Position in PAHC
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$330,919
+$65,253 QoQ
Shares Held
5,983
-15.9% QoQ
Ownership
0.015%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
5 quarters on record
Voting authority
Sole 8%
Shared 84%
None 8%
Common Shares in PAHC Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Cerity Partners LLC holds $67,490,391 across 30 Drug Manufacturers - Specialty & Generic names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
123,778 | $20,861,543 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
20,210 | $10,950,383 | |
| 3 | ZTS |
Zoetis Inc.
|
90,284 | $6,487,806 | |
| 4 | VTRS |
Viatris Inc
|
280,668 | $4,457,007 | |
| 5 | HLN |
Haleon plc
|
443,467 | $4,137,546 | |
| 6 | TEVA |
Teva Pharmaceutical Industries Ltd
|
106,508 | $3,608,490 | |
| 7 | RDY |
Dr Reddys Laboratories Ltd
|
184,772 | $2,677,345 | |
| 8 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
40,488 | $2,589,207 |
All Filings in PAHC
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $330,919 | 5,983 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $265,666 | 7,111 | Shares | Other | 2026-02-11 | |
| 2025-09-30 | $285,040 | 7,045 | Shares | Other | 2025-10-22 | |
| 2024-09-30 | $307,668 | 13,662 | Shares | Sole | 2024-11-12 | |
| 2024-03-31 | $143,445 | 11,094 | Shares | Sole | 2024-05-14 | |
| No filing history on record for this holder in this stock. | ||||||